Animation Baker and Instancing for Animated Characters: Using GPU to implement large-amount animation characters rendering. The animation map for vertex shader to modify the vertex position of the ...

One of those, a program for treating acute pain, could be particularly lucrative. But that prospect is now in question. Vertex ran a phase 2 clinical trial investigating the efficacy of its non ...

Prochazka (30-5-1 MMA, 4-2 UFC) and Hill (12-2 MMA, 6-2 UFC) will look to rebound from knockout losses to light heavyweight champion Alex Pereira when they square off Jan. 18 at UFC 311 from Inuit ...

The first UFC pay-per-view card on the 2025 schedule, UFC 311, appears to be fully booked with 14 fights. The January 18 fight card features two title fights at the top of the event. In the main ...

Merab Dvalishvili is seemingly nursing an injury ahead of UFC 311. The UFC bantamweight champion is set to defend his belt against 18-0-star Umar Nurmagomedov at the Intuit Dome in Inglewood ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

The FDA on Fri­day is­sued two si­mul­ta­ne­ous cys­tic fi­bro­sis ap­provals for Ver­tex Phar­ma­ceu­ti­cals but in­clud­ed high-lev­el safe­ty warn­ings for both.

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

Learning a new programming language offers more than just technical skills. It hones problem-solving abilities, enhances career prospects, and provides a deeper understanding of technology.

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...